Amarin Corporation plc (AMRN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 0.9209 |
| Open | 0.8500 |
| Bid | 0.8212 x 200 |
| Ask | 0.8322 x 400 |
| Day's Range | 0.8110 - 0.8700 |
| 52 Week Range | 0.6500 - 1.4900 |
| Volume | |
| Avg. Volume | 1,530,503 |
| Market Cap | 336.857M |
| Beta (5Y Monthly) | 2.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.08 |
ZacksAmarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
GuruFocus.comAmarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
GlobeNewswireAmarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host
© 2024 Yahoo. All rights reserved.